The role of dordaviprone in the multidisciplinary management of diffuse midline glioma Authors: Abdullah M. Al Lawati, Mohammed K. Al Suleimani, Iman A. Al Rasbi, Mohammed A. Al Hinai, Sara B. Al Marbouai, Hoor B. Al Barhi, Hanan M. Al Lawati, Ghusn S. Al Sideiri Published: 2026 ABSTRACT Background: Diffuse midline glioma (DMG) is a rare and aggressive pediatric and young adult brain tumor arising from midline structures of the central nervous system. Surgical resection is not possible due to its infiltrative nature, and radiotherapy remains the only standard treatment with limited benefit. Chemotherapy has failed to improve survival because of poor blood–brain barrier (BBB) penetration. Dordaviprone (ONC201), a dopamine receptor D type 2 (DRD2/3) antagonist and caseinolytic protease proteolytic (ClpP) agonist that crosses the BBB, has shown promising and durable activity in H3K27M-mutant DMG and was granted Food and Drug Administration accelerated approval in 2025.Methods: A structured narrative search of the literature was conducted using PubMed, Scopus, Google Scholar, and ClinicalTrials.gov from 2015 to 2025, with emphasis on studies published in the past 5 years. Search terms included ONC201, dordaviprone, H3K27M, H3 K27-altered DMG, ClpP, DRD2 antagonism, integrated stress response, and DMG clinical trials. Reference lists of key articles were also screened to identify additional sources.Results: Dordaviprone acts through dual mechanisms involving ClpP activation and DRD2 antagonism, leading to mitochondrial dysfunction and tumor cell death. It has demonstrated selective efficacy in preclinical and clinical studies, with manageable side effects such as fatigue, nausea, and headache. The drug is administered orally once weekly and is well tolerated.Conclusion: Dordaviprone offers a new targeted systemic therapy for DMG with proven safety, good tolerability, and meaningful clinical benefit. INTRODUCTION Diffuse midline glioma (DMG) is a rare, highly aggressive pediatric and young adult brain tumor. It arises in the midline structures of the central nervous system, including the pons, thalamus, and spinal cord. DMG is marked by diffuse infiltrative growth, making surgical resection impossible and resulting in a uniformly poor prognosis.[3,69] Although uncommon, DMGs remain a major clinical challenge, accounting for about 10–15% of pediatric brain tumors and an estimated 200–400 new cases in the United States annually.[44,69]Prognosis is poor, with a median overall survival (OS) of only 9–12 months despite advances in neuro-oncology over several decades.[44] At a molecular level, DMGs are defined by recurrent lysine-to-methionine substitutions at position 27 in histone H3 variants, most often in H3F3A (H3.3) and HIST1H3B/C (H3.1). These H3K27M mutations disrupt chromatin regulation and are the primary oncogenic drivers of this disease.[3,44,69] Recognition of this hallmark alteration led the 2016 World Health Organization classification to define “Diffuse Midline Glioma, H3K27M-mutant” as a Grade IV entity, updated in 2021 to “H3K27M-altered” to include mechanisms such as Enhancer of Zeste Homolog Inhibitory Protein overexpression.[47] Their location in midline structures, infiltrative growth, and limited blood– brain barrier (BBB) permeability restrict therapeutic options. Radiotherapy is the sole standard of care, underscoring the urgent need for new treatments.[3,44,69] Conventional external beam radiotherapy (54–60 Gy in 1.8– 2.0 Gy fractions) provides temporary neurological and quality-of-life improvement in most patients (70–80%), but these effects typically persist for <6 months before progression.[45]Meta-analyses confirm that radiotherapy extends median OS by only a few months compared to best supportive care, with mean OS rarely exceeding 12 months.[21,30] Chemotherapy has not meaningfully extended survival; agents such as temozolomide and carboplatin, alone or with radiotherapy, fail to improve outcomes compared to radiation alone.[22]The BBB remains a key obstacle, limiting drug penetration into tumor tissue.[51] The treatment landscape began to shift with routine tumor biopsies and molecular profiling, which revealed H3K27M mutations in H3F3A and HIST1H3B/C, present in 80% of DMGs. Building on these insights, dordaviprone (ONC201), a dopamine receptor D type 2 (DRD2) antagonist and caseinolytic protease proteolytic (ClpP) agonist that crosses the BBB, showed durable activity in recurrent H3K27M-DMG in several trials.[9,20] On August 06, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone, making it the first systemic therapy approved for this disease.[70] This review will examine the biological rationale, clinical evidence, and the evolving role of dordaviprone in the treatment of DMGs. Prior reviews and perspectives have summarized dordaviprone’s mechanistic rationale and early clinical signals in H3K27M-DMG and outlined ongoing confirmatory trials; however, an up-to-date synthesis integrating the FDA’s 2025 accelerated approval and evolving therapeutic positioning has not yet been consolidated. SEARCH STRATEGY A structured narrative search of the literature was conducted using PubMed, Scopus, Google Scholar, and ClinicalTrials. gov covering January 2015–October 2025, with emphasis on studies published within the past 5 years. Search terms included “ONC201,” “dordaviprone,” “imipridone,” “H3K27M,” “H3K27-altered diffuse midline glioma,” “ClpP,” “DRD2 antagonism,” “integrated stress response,” “DMG clinical trials,” and “ONC201 pharmacokinetics.” Reference lists of key articles were screened for additional sources. Given the rapidly evolving molecular and therapeutic landscape of DMG, a structured narrative approach was selected, enabling the integration of mechanistic, translational, and clinical evidence. The literature comprised English-language human studies, preclinical mechanistic research, clinical trials, observational cohorts, pharmacokinetic/pharmacodynamic (PK/PD) reports, and major review articles. The overall search strategy process is summarized in Figure 1. Literature search and study selection workflow. BIOLOGY OF DMG At the molecular level, H3K27M mutations in histone H3 variants are recurrent drivers of DMG.[17,63] These mutations disrupt chromatin regulation by impairing the polycomb repressive complex 2, which catalyzes H3K27me3 formation and maintains gene repression, leading to widespread loss of H3K27me3 and epigenetic reprogramming.[35,41] This dysregulation permits aberrant transcriptional activation, DNA hypomethylation, and loss of lineage commitment. Functional studies show that removal of H3K27M restores H3K27 methylation, suppresses proliferation, and abolishes tumorigenic potential, underscoring its essential role in gliomagenesis.[35] Downstream, H3K27M mutations promote tumor invasion and migration by activating developmental signaling pathways, such as the β-catenin/ubiquitin-specific protease 1 pathway, while sustaining stem-like properties and blocking differentiation.[12,66] These molecular alterations translate clinically into aggressive, infiltrative growth and resistance to conventional therapies. MECHANISM OF DORDAVIPRONE Dordaviprone acts through a dual mechanism involving mitochondrial stress induction and disruption of dopamine receptor-mediated survival signals. Together, these interactions converge on activation of the integrated stress response (ISR) and induction of apoptosis in H3K27-altered DMG cells. Dordaviprone’s two primary molecular targets are the mitochondrial ClpP and the G-protein-coupled DRD2, both of which are highly relevant to the metabolic and epigenetic vulnerabilities of DMG. Dordaviprone as a CLpP activator DMG cells have high energy needs; thus, they produce adenosine triphosphate (ATP) through the mitochondrial respiratory chain and the tricarboxylic acid cycle.[40] A proton gradient is created across the inner mitochondrial membrane as a result of this action, which also produces nicotinamide adenine dinucleotide and releases hydrogen.[40,48] Molecular chaperones within mitochondria refold misfolded proteins, while proteases such as ClpP destroy those that are beyond repair.[6] ClpP is a mitochondrial serine protease located in the matrix and is essential for maintaining protein quality.[6] In physiological conditions, ClpP forms a tetradecameric cylindrical structure composed of stacked heptameric rings, creating a hollow core capped by the ATP-dependent unfoldase caseinolytic protease regulatory subunit X (ClpX) at one or both ends. This ClpXP complex consists of two subunits: ClpP and ClpX.[6,15] Within ClpP, a hydrophobic pocket, the H-site, serves as an attachment site for the ClpX subunit, facilitating complex activation and mediating substrate selection.[6,15,48,73] ClpX functions as a recognition and translocation unit, binding damaged or misfolded polypeptides, using ATP hydrolysis to unfold them, and inserting them into the ClpP catalytic chamber for regulated degradation.[6,48,74] In H3K27M-mutant DMG, increased metabolic and proteostatic stress is reflected in elevated ClpP expression.[37,40]Dordaviprone selectively interacts with ClpP at the H-site, displacing ClpX as drug concentration rises.[55] Axial pores expand upon dordaviprone binding to ClpP, enabling more proteins to enter the complex and displacing the standard regulator (ClpX).[40,58] ClpP then becomes hyperactive and nonspecific, degrading essential mitochondrial proteins, including succinate dehydrogenase (SDH)A and SDHB, components of Complex II in the electron transport chain, as well as misfolded proteins. These changes disrupt mitochondrial function and ATP generation, leading to a decline in oxidative phosphorylation and accumulation of reactive oxygen species (ROS), which induces mitochondrial failure and tumor cell death.[55,58] Furthermore, CRISPR/Cas9-mediated ClpP knockdown in DMG cell lines eliminates dordaviprone’s anticancer activity in previously sensitive cells, confirming ClpP as the primary molecular target.[24,28] Dordaviprone as a DRD2 antagonist Dordaviprone has been reported to target DRD2 in nonDMG cancer cell lines.[57] DRD2 is a G protein-coupled receptor that inhibits cyclic adenosine monophosphate (cAMP) synthesis through Gαi-mediated suppression of adenylate cyclase.[49] DRD2 expression is significantly higher in H3K27M-mutant DMGs than in wild-type gliomas.[55] Dordaviprone binds to both orthosteric and allosteric residues within DRD2 binding sites, enabling tight molecular docking.[58] Beyond cAMP suppression, D2-like receptors regulate potassium and calcium channels, activate phospholipase C to increase intracellular calcium levels, and signal through β-arrestin, which facilitates receptor recycling and sensitization.[23,68] By antagonizing DRD2, dordaviprone prevents adenylate cyclase inhibition, restoring cAMP levels and disrupting survival signaling.[57] This blockade activates the ISR, promoting proapoptotic signaling.[43,46]Dordaviprone further amplifies ISR activation downstream of DRD2 antagonism while concurrently inactivating Akt/ERK and other pro-survival pathways.[46] Moreover, in tumor studies, dordaviprone shows a broader therapeutic index than antipsychotics.[18] At concentrations compatible with its anticancer activity, it exerts both competitive and noncompetitive DRD2 antagonism, as shown by Schild analysis and radioligand competition assays.[56] G-protein coupled receptors (GPCR) screening demonstrates that dordaviprone selectively targets DRD2 without affecting other GPCRs, supporting its specificity, favorable safety profile, and tumor-cell selectivity compared with traditional DRD2 antagonists.[18,58] Dordaviprone as an ISR activation activator Dordaviprone promotes cellular stress and failure by inducing mitochondrial dysfunction and ROS buildup, which damages mitochondrial DNA and lipids. The ISR triggered by this stress is characterized by the phosphorylation of eIF2α and the activation of the transcription factors ATF4 and CHOP.[29,55] While the ISR primarily affects metabolic and cytoprotective pathways, these factors induce proapoptotic genes such as TRAIL, thereby promoting apoptosis.[19,28] ATF4 coordinates both death and adaptive signals by regulating CHOP, an essential mediator of apoptosis induced by endoplasmic reticulum and mitochondrial stress, and by enhancing translation of genes involved in energy utilization and proliferation.[40,67] Prolonged ISR activation under dordaviprone exposure shifts the cellular response from adaptive recovery toward apoptosis, preventing tumor cells from surviving or proliferating.[59] The ISR serves as the convergence point for dordaviprone’s dual mechanisms: integration of ClpP hyperactivation and DRD2 antagonism ultimately induces tumor cell death. PRECLINICAL AND TRANSLATIONAL EVIDENCE Preclinical rationale in DMG Preclinical studies support the effectiveness of dordaviprone as a therapy for DMG. ClpP is a key biomarker of response, as it is significantly overexpressed in these cancers and correlates with treatment sensitivity.[37] A key epigenetic feature of H3K27M mutant DMG has been addressed by reversing the loss of H3K27me3 after exposure to dordaviprone.[40] In addition, the drug enhances the infiltration of cytotoxic T and NK cells into the tumor microenvironment, revealing that it may have immunomodulatory effects.[71,72] Furthermore, this synergistic effect has been observed whether paired with radiation, PI3K/Akt inhibition, or epigenetic inhibitors, supporting its rationale for clinical use.[37,60] Broader preclinical evidence and FDA rationale Beyond DMG, broader preclinical investigations established dordaviprone as a new class of anticancer drugs termed imipridones.[53] Preclinical studies provided a strong scientific rationale for its clinical development by demonstrating a multifaceted mechanism of action that selectively targets cancer cells while sparing healthy tissue. Dordaviprone exhibits broad-spectrum anticancer activity across multiple tumor models, including hematological, colorectal, and glioblastoma cell lines.[2,13] Notably, it demonstrates p53-independent cytotoxicity in glioblastoma, including the temozolomide-resistant T98G line.[2] Co-administration with bevacizumab maintains anti-tumor effects in xenografts, suggesting a complementary, nonoverlapping mechanism.[2] Subsequent studies further clarified dordaviprone’s dual mechanism, ClpP activation, and DRD2 antagonism, which collectively induce mitochondrial stress, TRAIL/DR5 upregulation, and apoptosis.[11,32,33] Furthermore,preclinical studies have demonstrated its high efficacy against H3K27M-mutant DMG, a brain tumor associated with poor prognosis.[1,58] Clinical trials Moving into clinical trials, dordaviprone has been evaluated in several early-phase studies that ultimately supported its accelerated FDA approval. In the first human phase I trial of dordaviprone, it was administered at a 3-weekly dose range of 125–625 mg to patients with several treatment-refractory solid tumors such as endometrial and prostate cancer.[64] A primary objective of the study is to determine the recommended phase II dose (RP2D) of dordaviprone in patients with advanced malignancies, with other aims including assessing its PK and PD profiles. The study progressed across five escalating dose levels ranging from 125 mg to 625 mg, with a single patient treated at each level. It concluded with an expansion cohort of 18 patients with advanced cancer enrolled at the highest dose of 625 mg. Findings from this analysis identified 625 mg as the RP2D, supported by a favorable safety profile, attainment of therapeutically acceptable plasma concentrations, early signs of tumor engagement, and sustained PD effects.[64]The primary adverse effects associated with dordaviprone included nausea, vomiting, and elevated serum amylase; these were predominantly grade 1 and were promptly managed. The principal outcome indicated that dordaviprone provided clinical benefit with a manageable safety profile, warranting further improvement.[64] Subsequent research expanded to specific tumor types, notably glioblastoma, the most prevalent primary malignant brain tumor in adults. Despite FDA-approved therapies, the median survival for glioblastoma remains only 14.6 months.[5] A phase II study subsequently evaluated the efficacy of dordaviprone in patients with recurrent glioblastoma who had exhausted standard treatments, including surgery, radiation, and chemotherapy.[9] Thetrial enrolled 17 patients with recurrent IDH1/2 wild-type glioblastoma, each receiving dordaviprone at 625 mg every 3 weeks. Bevacizumab was not administered, isolating the effects of dordaviprone. Key outcomes included two patients achieving 3-month progression-free survival (PFS) and continued therapy beyond 11 months, resulting in a PFS6 rate of 11.8%.[9] Interestingly, a 22-year-old female patient with an H3.3 K27M-mutant grade II astrocytoma showed particularly encouraging results and provided a rationale for further clinical testing of dordaviprone in this population, which has historically had dismal outcomes.[9] After receiving seven doses of dordaviprone, she achieved a “partial response” measured by response assessment in neuro-oncology (RANO), with an 85% reduction in tumor size that has been maintained for over 6 months.[9] Furthermore, an integrated study demonstrated that dordaviprone led to more than a 50% reduction in corticosteroid use and improved performance status in patients with H3K27M-mutant DMG, indicating a clinically meaningful benefit.[8] The ongoing ACTION trial is a phase III, randomized, double-blind, placebo-controlled study evaluating dordaviprone in newly diagnosed pediatric and adult patients with H3K27M-mutant diffuse glioma.[8] Its primary goal is to assess whether dordaviprone improves overall and PFS relative to placebo.[8] The study is anticipated to further establish the therapy’s potential to prolong survival and deliver meaningful clinical benefit, with the expectation that its findings will validate the promising efficacy signals observed in earlier-phase investigations. The principal clinical trials evaluating dordaviprone across DMG and related glioma populations are summarized in Table 1.[8,9,10,31] Table 1:Summary of key clinical trials evaluating dordaviprone (dordaviprone) in DMG and related glioma subtypes. Summary of key clinical trials evaluating dordaviprone (dordaviprone) in DMG and related glioma subtypes. PRACTICAL CLINICAL USE Dordaviprone is available as oral capsules (125 mg per capsule) administered once weekly.[27] The recommended dose for adults and pediatric patients is shown in Table 2.[27,58,59] Table 2:Weight-based dosing recommendations for dordaviprone. Weight-based dosing recommendations for dordaviprone. For patients unable to swallow whole capsules, the contents may be opened and dissolved in 15–30 mL of an appropriate diluent (water, apple juice, or sports drinks) for oral or enteral administration.[58,59] This simplified once-weekly oral therapy is substantially more practical than conventional chemotherapy, which requires hospitalization, multiple infusions, and intensive monitoring. Ongoing research is exploring liquid formulations of dordaviprone. A nicotinamide-based oral solution has demonstrated greater solubility and stability in preclinical models and early compassionate-use settings, though it remains unapproved.[60] Safety and clinical monitoring Clinical monitoring during therapy includes cardiac, hematologic, and reproductive assessments. Baseline and follow-up electrocardiograms are recommended to monitor for QTc prolongation, particularly in patients with risk factors or on QT-prolonging drugs.[55] Reported hematologic abnormalities may include lymphopenia and, less commonly, neutropenia. Transient elevation in amylase, alanine aminotransferase, and aspartate aminotransferase has also been observed.[11] No human pregnancy data are yet available. However, animal studies in rats and rabbits exposed to oral dordaviprone at doses below clinical levels showed increased fetal mortality and malformations during organogenesis. Therefore, patients of reproductive potential should be counseled to use effective contraception during treatment and for 1 month after the final dose.[58] Treatment response and drug interactions Treatment response is primarily assessed by magnetic resonance imaging (MRI) using RANO-HGG or RANO 2.0 criteria. Circulating H3K27M cell-free tumor DNA in plasma or cerebrospinal fluid (CSF) is emerging as a promising biomarker to monitor treatment response and relapse.[55,61] No significant CYP450-mediated drug–drug interactions have been identified, but concomitant use of QT-prolonging or dopamine-modulating drugs should be avoided.[25,58] IMPLICATIONS FOR NEUROSURGICAL PRACTICE Dordaviprone introduces several practical considerations for neurosurgeons managing H3 K27–altered DMG. Tissue diagnosis remains essential, as stereotactic biopsy is required to confirm H3 K27-altered status and determine eligibility for dordaviprone and clinical trials.[21] Understanding the drug’s delayed-onset activity also helps neurosurgeons differentiate true progression from postradiotherapy pseudoprogression, avoiding premature treatment changes.[30,45] Neurosurgeons continue to play a critical role in managing complications such as hydrocephalus or rapid neurological decline, where CSF diversion procedures can be safely performed without interrupting dordaviprone therapy.[21]These considerations position neurosurgery as an essential component of multidisciplinary DMG care in the era of targeted therapy.[21] PLACEMENT IN THE CURRENT TREATMENT ALGORITHM DMG with an H3K27M mutation is currently being managed with palliative care, prioritizing symptom relief and prolonging survival. The aggressive nature of this condition prompted researchers to develop a current treatment algorithm to maximize patients’ survival. There are several pathways to managing recurrence after radiotherapy, including dordaviprone, re-irradiation, or participation in clinical trials exploring new drugs. A recent study illustrated that pediatric patients receiving a second course of radiotherapy were associated with better survival and enhanced neurological recovery.[16] However, not every patient is suitable to undergo radiotherapy again. Considerations such as the duration since the last radiotherapy, dose limitations, toxicity experienced, and patient characteristics must be taken into account.[62] In addition, there is a nonnegligible increased risk of radiation necrosis.[7,61] On the other hand, dordaviprone can be used as it has been proven to be safe and well-tolerated with no significant toxicity related to dose escalation.[61] Data from multiple early-phase trials indicate that approximately one-third of patients treated with dordaviprone were alive at 24 months, demonstrating that this systemic agent provides a durable clinical benefit for certain patients.[9] Dordaviprone is given orally once weekly.[52,54] This straightforward regimen makes using the drug convenient. It facilitates patient and caregiver education, enhancing its practicality as a treatment option. Beyond the current available therapies, novel systemic agents are under investigation. Panoinostat, a histone deacetylase inhibitor, demonstrated strong anti-tumor effects in preclinical studies and advanced to phase 1 clinical trials. Despite its ability to shrink the tumor, the dose required to achieve this effect is toxic. Well-tolerated doses were ineffective in extending survival duration.[65] Likewise, GD2-CAR T-cell therapy shows promising anti-tumor activity. However, it causes severe toxicity called tumor inflammation-associated neurotoxicity.[36] By contrast, dordaviprone has mild side effects, including fatigue, headaches, nausea, and vomiting.[50] Hence, compared with other complex strategies such as re-irradiation and investigational agents in clinical trials, dordaviprone is a safer and better-tolerated option. Dordaviprone is approved for both pediatric and adult patients.[50] Unlike adult patients, whose autonomy determines medication choices, decisions regarding the treatment of children are made by their families or legal guardians. For this reason, clear communication is essential to facilitate informed decisions. Clinical decision-making may be hindered by challenges linked to drug administration in pediatric patients. As a result,researchers developed an oral solution of dordaviprone using nicotinamide to enhance its solubility and stability. This strengthens its role in therapeutic decision-making, as it is suitable for pediatric patients with DMG who have swallowing issues.[14] Adults often have comorbidities, which must be taken into account before commencing dordaviprone. For instance, a study compared patients with severe renal impairment to patients with normal renal function receiving dordaviprone and found that the systemic drug exposure was increased by 50% in patients with renal impairment.[4] Therefore, comorbid illnesses may influence the safety and adverse-effect profile of dordaviprone, and this must be considered when making a clinical decision. Furthermore, patients on multiple medications must be careful when starting dordaviprone as some may cause drug-to-drug interactions. For instance, potent CYP3A4 inhibitors, such as itraconazole, increase dordaviprone exposure, whereas CYP3A4 inducers, such as rifampicin, reduce it.[26] Such interactions may alter the benefit-to-risk ratio of dordaviprone, emphasizing the need for individual assessment. Even though relapse is common, it is often difficult to distinguish it from treatment-induced imaging changes. A phenomenon called pseudo-progression occurs when MRI scans show changes that mimic tumor progression, misleading the physician into discontinuing treatment or starting therapy prematurely. Factors including absence of symptoms, MGMT promoter methylated, and decreased cerebral blood volume increase the likelihood of pseudo-progression.[50] Similarly, radiation necrosis can be mistaken for tumor progression. Radiation necrosis can develop as an adverse effect after undergoing radiotherapy treatment. In parallel with pseudo-progression, reduced cerebral blood volume may help differentiate radiation necrosis from actual progression.[42] The current treatment pathway integrating dordaviprone into multidisciplinary management of H3 K27-altered DMG is summarized in Figure 2.[4,7,9,14,16,26,36,42,54,56,61,62,65] Proposed multidisciplinary treatment algorithm for diffuse midline glioma incorporating dordaviprone. FUTURE DIRECTIONS In the future, research should place greater emphasis on evaluating the long-term effectiveness and safety of dordaviprone in the treatment of DMG. This can be achieved through systematic documentation of patient-reported outcomes and quality-of-life measures, which will help refine subsequent clinical decisions. Although dordaviprone shows promise, one study reported an objective response rate of only 20%, indicating that not all patients respond adequately to monotherapy.[9,34] A possible explanation is metabolic adaptation through activation of the PI3K/Akt pathway. Therefore, combining dordaviprone with a PI3K/Akt inhibitor such as paxalisib may help overcome this resistance.[38-40] Future studies should prioritize identifying optimal combination strategies to maximize therapeutic benefit. To distinguish responders from nonresponders, the development of predictive biomarkers will be essential for individualized care. While ClpP expression may predict sensitivity to the drug, preclinical evidence suggests that TP53 mutations could confer resistance.[34,40] Larger clinical cohorts are needed to confirm these observations. CONCLUSION Dordaviprone represents an important advance in the management of DMG, translating molecular insights into a systemic, targeted therapy with manageable toxicity. Its dual mechanism targeting mitochondrial proteostasis and dopaminergic signaling positions it as a promising backbone for future multimodal treatment strategies, pending confirmation from ongoing phase III studies.